LYoxatin 150mg/30ml Bidiphar treatment for supplementary colon cancer III, Great Cancer - Late Rectum (30ml)

Dosage form Box x 30ml
Specifications Oxaliplatin

Ingredient

Composition informationContent
Oxaliplatin150mg

Uses

Indications

Supplementary treatment of colon cancer stage III:

Oxaliplatin combined with fluorouracil and leucovorin used in the third stage of stage of colon cancer treatment in patients has surgery to thoroughly surgery.

Treatment of late colon cancer:

Leading therapy: Oxaliplatin is used in combination with fluorouracil and leucovorin to treat late-roly cancer, before untreated, unprocessed.

The second row therapy: Late colorectal cancer relapses or progresses within 6 months after the leading therapy with combination of fluorouracil, leucovorin and irinotecan.

Currently, data has not seen clinical benefits.

Pharmacological

No data.

pharmacokinetics

No data.

Before taking LYoxatin 150mg/30ml Bidiphar treatment for supplementary colon cancer III, Great Cancer - Late Rectum (30ml)

How to use

Oxaliplatin is used by intravenous line for 2 hours. Dilute right before use. Do not use sodium chloride solution or solutions containing chloride to dilute. Do not use needles and aluminum infusion kits because of the ability to decompose platinum.

Before use, take the drug calculated from the solution of 5mg/ml and dilute into 250 - 500 ml of 5%Dextrose solution. The diluted solution can be stored in the refrigerator up to 24 hours and at room temperature for about 6 hours. The mixed solution must be checked to the sensory before injecting, remove this vial if there is still still or discoloration. Do not mix or put other drugs into the same intravenous line with Oxaliplatin. Before the transmission of oxaliplatin or other drugs simultaneously, it is necessary to clean the intravenous line with a 5%dextrose solution.

Avoid direct contact with the drug during the preparation. If the drug solution is in direct contact with the skin, the mucosa must wash the skin with soap and water, washing the mucosa by rinse with plenty of water.

Dosage

Due to the Oxaliplatin, Fluorouracil and Leucovorin coordination regimen, causing the rate of nausea and vomiting at a higher level of 3/4 than the regimen including Fluorouracil and Leucovorin, so each 2 -day regimen needs to use Serotoninergic Serotoninergic Serial Inhibition

Oxaliplatin, fluorouracil and leucovorin (Folfox 4) regimen is used for 2 consecutive days. The 2 -day regimen can be repeated after 2 weeks.

Day 1: Oxaliplatin 85 mg/m2 and Leucovorin 200 mg/m2 (diluted with 5%dextrose) are used simultaneously (in 2 separate transmission bags, using a medical kit), intravenous transmission for 2 hours. Next, fluorouracil 400 mg/m2 injected directly into the vein for 2-4 minutes and then the fluorouracil intravenously 600 mg/m2 (diluted with 500 ml of 5%dextrose) for 22 hours.

Day 2: (Do not use oxaliplatin), Leucovorin 200 mg/m2 intravenously for 2 hours. Next, fluorouracil 400 mg/m2 injected directly into the vein for 2-4 minutes and then the fluorouracil intravenously 600 mg/m2 (diluted with 500 ml of 5%dextrose) for 22 hours.

For supplementary treatment of great cancer - rectal cancer stage III after radical surgery, using 12 cycles (6 months). In patients with late colorectal cancer treatment, it is recommended to use this regimen until the signs of disease progression or the drug is not tolerant.

To treat late colorectal cancer or complementary colorectal cancer, you can use a replacement regimen. The transformer folfox 6 regimen is also used for 2 consecutive days. Oxaliplatin 85 mg/m2 and Leucovorin 400 mg/m2 (or 350 mg/m2, diluted with 5%dextrose) are used simultaneously (in 2 separate transmission bags, using a Y chumids), intravenous transmission for 2 hours. Next, fluorouracil 400 mg/m2 intravenously for 5 minutes. Then fluorouracil intravenously 1,200 mg/m2/day for 2 days. Total dose of fluorouracil 2.800 mg/m2/cycle.

Dosage of conversion to reduce toxicity: may have to change the dose or time to transmit oxaliplatin to limit some unwanted effects of the drug (such as sensory toxicity, digestion and hematopoietic system). Increasing oxaliplatin transmission time from 2 hours to 6 hours can minimize acute toxicity; No need to adjust the transmission time of fluorouracil or leucovorin.

Additional treatment of cancer - Rectal stage III:

In patients with cancer - Rectal stage III (after surgery supplementary treatment) has an unwanted effect on the persistent peripheral sensory level 2, reduces the dose of oxaliplatin to 75 mg/m2 and considers the stopping of the drug if the toxicity is at level 3.

On patients with cancer - stage III (after surgical supplementary treatment) with a third or 4 -level digestive toxicity (appearing even after prophylactic treatment), neutropenia level 4 levels, level 3 or 4 platelets, oxaliplatin dose is required to 75 mg/m2 and decrease the dose of fluorouracil 20% (for example 300 mg/m2 injecting in 22 hours) in 22 hours). Using the next dose must slow down when the number of neutrophils ≥ 1,500/mm3 and the amount of platelets ≥ 75,000/mm3.

Treatment of great cancer - rectal:

In patients with advanced colorectal cancer, there is an unwanted effect on the persistent peripheral sensory level 2, it is necessary to reduce the dose of oxaliplatin to 65 mg/m2 and consider stopping the drug if the toxicity is at level 3. No need to change the dose of fluorouracil or leucovorin.

In patients with late - rectal cancer patients (after surgery supplementary treatment) with a level of gastrointestinal level 3 or 4 (appear even after prophylactic treatment), neutropen leukemia level 4, platelet reduction level 3 or 4, need to reduce the dose of oxaliplatin to 65 mg/m2 and reduce the dose of fluorouracil 20% (for example 300 mg/m2 in injection of 5 mg/m2 in 22 hours) in 22 hours). Using the next dose must slow down when the number of neutrophils ≥ 1,500/mm3 and the amount of platelets ≥ 75,000/mm3.

There is no assessment of the safety and effectiveness of the drug in patients with renal failure. So far, there has been no recommendation on the adjustment of the dose on patients with renal failure. People with renal failure have creatinine clearance

No need to adjust the dose for patients with liver failure.

No dose adjustment for elderly patients (over 65 years old) is used in combination with oxaliplatin, fluorouracil and leucovorin in the treatment regimen of great cancer and rectum.

What to do when overdose?

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double doses to compensate for missed dose.

Side Effects

Notify the physician the unwanted effects when using the drug.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Hypersensitivity to oxaliplatin, platinum derivatives and any ingredients of the drug.

Pregnant women, breastfeeding period.

severe renal failure (CLCR

Be cautious when used

Due to the toxicity of anti -cancer drugs, it is necessary to be cautious when exposed to drugs and waste from drugs (needles pumps, vials ...). Use gloves, masks or protective glass when exposed to the drug.

Oxaliplatin must be used by a specialist, with experience in supervision.

Because Oxaliplatin is in the coordination regimen with fluorouracil and leucovorin, it is necessary to consider the relevant information of these drugs.

Oxaliplatin treatment is often accompanied by two types of primary peripheral sensory disorders. Time and severity of the disease increases with the dose. Peripheral sensory neurological disorders occur for 92% of users of oxaliplatin combination regimen with fluorouracil and leucovorin to treat colon cancer. The acute peripheral sensory neurological disorder is reported on 56% of users who coordinate with abnormal manifestations, sympathy, reducing sensation in the hands, feet, around the mouth or throat, jaw stiff, taste disorders, voiced disorders, eye pain and chest tightness. These symptoms appear within hours to 1-2 days after taking the drug, recovering (within 14 days) and may recur in the next doses. Because these symptoms are often aggravated when exposed to cold temperatures (including inductance - throat - larynx), it is necessary to advise patients to avoid food, cold drinks, avoid exposure to cold temperatures, gloves when holding cold objects. When transmitting oxaliplatin, do not apply cold to prevent mucosa. It is possible to prolong the transmission time to reduce the proportion of inductance - throat - larynx. The persistent neurological disorder has been reported over 48% of the user of a combination regimen, more persistent symptoms (over 14 days), often affecting daily activities (such as writing, installing shirts, swallowing, walking), these symptoms can improve if the drug stops. Preventive measures to reduce the rate and level of toxicity on the nerves of oxaliplatin include oxaliplatin dosage mode and neurological modulation drugs (such as amifostin, carbamazepine, gabapentin, glutathion) so far are not evidence. Calcium gluconate and Magnesi sulfate intravenously before and after oxaliplatin transmission may reduce nerve toxicity but may also have a negative effect on clinical response and anti -cancer activity.

The drug can cause pulmonary fibrosis. If the respiratory manifestations are not explained (such as dry cough, shortness of breath, darkening on the lung X-ray), it is necessary to suspend the drug until the elimination of pulmonary fibrosis.

The drug can be toxic to the liver (including liver failure and hepatitis). Consider the possibility of liver vascular disorders (including veins), especially in people with drama hypertension or liver enzyme increased. Before each treatment cycle with oxaliplatin should be tested for liver function assessment.

Users combine Oxaliplatin, Fluorouracil and Leucovorin often have more platelets and bleeding than the regimen including Fluorouracil and Leucovorin. Blood formula test (eg white blood cell formula, platelet quantity) and blood biochemistry (including ALT, AST, Bilirubin and Creatinin) before each treatment cycle. Patients use simultaneously containing oxalipaltin, fluorouracil and leucovorin regimen with oral anticoagulant drugs that need to closely monitor prothrombin and INR.

Use carefully for people with kidney failure because the drug can increase toxicity on this object.

When transmitted continuously, it is recommended to use Taxan (Docetaxel, Paclitaxel) before the platinum derivatives (Carboplatin, cisplatin, Oxaliplatin) to limit the risk of marrow failure and increase effectiveness.

The simultaneous use of Oxaliplatin with 5-Fluorouracil may increase the risk of unwanted effects on the liver and the digestive tract.

Elderly patients are often more sensitive to some unwanted effects of the drug including diarrhea, dehydration, hypokalemia, leukopenia, fatigue, fainting.

The effect and safety of oxaliplatin for children have not been set up.

The effect of the drug on driving and operating machinery

No data.

Use drugs for women during pregnancy and lactation

No data.

Drug interaction

drug interactions can affect the activity of the drug or cause side effects.

Patients should notify the doctor or pharmacist a list of the drugs and functional foods you are using. Do not use or increase or decrease the dose of the drug without the guidance of a doctor.

Storage

Leave a cool place, avoid light, temperature below 30⁰C.

To be out of reach of children, read the user manual carefully before use.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

count views

Popular Keywords